An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
On August 9, U.S. Senator Maggie Hassan toured Novocure's U.S. headquarters in Portsmouth, New Hampshire, discussing the company's innovative cancer treatments. Hassan emphasized the importance of expanding access to medical technologies and acknowledged Novocure's role as a job creator in New Hampshire. Novocure, headquartered in Switzerland, focuses on extending survival for patients with aggressive cancers through Tumor Treating Fields therapy, with products approved for glioblastoma and malignant pleural mesothelioma. The company also conducts trials for various other cancers.
Positive
Sen. Hassan's visit highlights Novocure's commitment to cancer treatment innovation.
Expansion of patient access to revolutionary therapies could boost market presence.
Recognition of Novocure as a job creator enhances its reputation.
Negative
None.
Sen. Hassan toured the company’s U.S. headquarters in Portsmouth before meeting and speaking with employees
ROOT, Switzerland--(BUSINESS WIRE)--
On Tuesday, Aug. 9, U.S. Sen. Maggie Hassan (NH) joined members of Novocure’s leadership team to tour the company’s U.S. headquarters in Portsmouth, New Hampshire, and learn more about Novocure’s groundbreaking work to extend patient survival in some of the most aggressive forms of cancer.
Following the tour, Sen. Hassan met with Novocure employees to answer questions and provide an update on her work in Washington. In her remarks, Sen. Hassan spoke about the importance of expanding patient access to innovative medical technologies as well as Novocure’s impact as an innovative job creator in New Hampshire.
“It was great visiting Novocure to learn more about the innovative work being done here for the health and well-being of Granite Staters and Americans,” said Sen. Hassan. “I am focused on working across the aisle in order to improve our health care services and technology so that companies like Novocure can continue their critical work. I appreciated the opportunity to speak with Novocure and their staff about how we can keep working together to strengthen health care and support innovative technology to improve health care outcomes.”
“We thank Sen. Hassan for her continued leadership and dedication to ensuring that patients are afforded timely access to the most revolutionary cancer-treating therapies on the market,” said Bill Doyle, Novocure’s Executive Chairman. “Novocure is proud to have Sen. Hassan representing New Hampshire on Capitol Hill, where she continues to champion the needs of patients everywhere. We were honored to host Sen. Hassan here to share more about Novocure’s patient-forward culture of growth and our commitment to bringing more high-quality jobs to the Granite State. We look forward to having her back in Portsmouth for another visit soon.”
About Novocure:
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.
What did Sen. Hassan discuss during her visit to Novocure on August 9?
Sen. Hassan discussed expanding patient access to innovative cancer treatments and Novocure's impact as a job creator in New Hampshire.
What is Novocure known for in the oncology sector?
Novocure is known for its Tumor Treating Fields therapy, which aims to extend survival in aggressive cancers like glioblastoma and malignant pleural mesothelioma.
Where is Novocure's U.S. headquarters located?
Novocure's U.S. headquarters is located in Portsmouth, New Hampshire.
What types of cancer is Novocure conducting clinical trials for?
Novocure is conducting trials for brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
How does Sen. Hassan's support affect Novocure's operations?
Sen. Hassan's support may enhance Novocure's ability to expand access to its therapies and strengthen its role in the healthcare sector.
